BCIQ Profiles

Company Profile Report

FDA lifts hold on Phase I/II of axalimogene filolisbac for SCCHN

Advaxis Inc. (NASDAQ:ADXS) said FDA lifted a clinical hold on a Phase I/II combination study that includes the company's axalimogene filolisbac (ADXS11-001).


Read the full 223 word article

How to gain access

Continue reading with a
two-week free trial.